Physician profile
Rishabh Gulati
NPI 1649688698
$4,530.35
in general payments reported to CMS, 2019-2025
23 companies · $2,630 in 2025
The $2,630 reported for 2025 was more than what 85% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $400 · 2020: $149 · 2022: $107 · 2023: $90.48 · 2024: $1,154 · 2025: $2,630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,127 · Consulting Fee: $1,650 · Travel and Lodging: $97.82.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,126.57 |
| Consulting Fee | $1,650.00 |
| Travel and Lodging | $97.82 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $2,246.04 | 2024-2025 | Tremfya, Stelara |
| Abbvie INC. | $636.13 | 2019-2025 | |
| Genzyme Corporation | $268.62 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.97 | 2023-2025 | Entyvio, Eohilia |
| Phathom Pharmaceuticals, INC. | $167.93 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $133.77 | 2024-2025 | Rezdiffra |
| Exelixis INC. | $124.04 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.29 | 2024-2025 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $110.74 | 2024 | |
| Pfizer INC. | $94.37 | 2023-2025 | |
| Celgene Corporation | $79.35 | 2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $54.69 | 2024-2025 | Dupixent |
| Lilly USA, LLC | $41.61 | 2024-2025 | Omvoh, Zepbound |
| Olympus America INC. | $40.33 | 2022-2024 | Endoclot Phs |
| Boston Scientific Corporation | $31.87 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $30.91 | 2025 | Gi Genius |
| Aimmune Therapeutics, INC. | $30.54 | 2024-2025 | Vowst |
| Qol Medical, LLC | $24.15 | 2025 | Sucraid |
| Gilead Sciences, INC. | $22.34 | 2022 | |
| Braintree Laboratories, INC. | $20.60 | 2022 | |
| Erbe USA INC | $15.89 | 2024 | |
| Intercept Pharmaceuticals, INC. | $13.17 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$17,523.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rishabh Gulati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.